New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
09:49 EDTBCRXBioCryst, HHS extend peramivir agreement for 31 days
BioCryst Pharmaceuticals disclosed that it and the U.S. Department of Health and Human Services mutually agreed to extend their agreementís current expiration date of February 28 for 31 days. The new expiration date is changed to March 31. The extension of the agreement will allow ongoing stability testing of peramivir to continue beyond the current contract expiration date. All other terms and conditions of the agreement remain unchanged.
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
09:20 EDTBCRXOn The Fly: Pre-market Movers
Subscribe for More Information
06:27 EDTBCRXBioCryst volatility flat into CDC confirms first U.S. Ebola case in Texas
Subscribe for More Information
September 30, 2014
18:36 EDTBCRXOn The Fly: After Hours Movers
Subscribe for More Information
17:58 EDTBCRXCDC confirms first U.S. patient diagnosed with Ebola virus
Subscribe for More Information
17:39 EDTBCRXCompanies developing Ebola treatments rise after CDC confirms U.S. Ebola case
Subscribe for More Information
16:47 EDTBCRXBioCryst up 5% after hours following CDC confirmation of Ebola case in U.S.
Subscribe for More Information
September 26, 2014
07:47 EDTBCRXEMA to review BioCryst, Sarepta, Tekmira experimental Ebola medicines
Subscribe for More Information
September 18, 2014
12:08 EDTBCRXBioCryst receives additional NIAID funding for BCX4430
BioCryst announced that the National Institute of Allergy and Infectious Diseases exercised two additional options under its contract, which provides for GMP drug substance and drug product manufacture of BCX4430. Exercise of these options includes up to a $2M increase to the existing development contract. The contract modification and the two additional options exercised represent up to $4M to BioCryst in order to accelerate the development of BCX4430 as a treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease. NIAID, part of the National Institutes of Health, granted this five year term contract to BioCryst in September 2013. Approximately $19.9M of funding has been awarded to date under the contract. With this additional award, the BCX4430 development contract has been increased in value to $26.3M, if all options are exercised. This project is funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300017C.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use